Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GU03-67

A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

  • N. M. Hahn, C. Whalen, C. J. Sweeney. Second-line pemetrexed (P) for the treatment of hormone refractory prostate cancer (HRPC): A Hoosier Oncology Group GU03-67. Preliminary analysis. Presented at the general poster session at the ASCO Annual Meeting, June 2-6, 2006, Atlanta, Georgia J Clin Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4644.
  • N.M. Hahn, F. Ademuyiwa, R.T. Zon, T. Jones, W. Dugan, C. Whalen, M. Yu, R. Shanmugam, T. Skaar, C.J. Sweeney. A Multicenter Phase II Study of Pemetrexed for the Treatment of Hormone Refractory Prostate Cancer (HRPC) with Reduced Folate Carrier 1 (RFC1) Pharmacogenetic Analysis: GU03-67. Accepted to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL

Manuscripts/Articles:

  • ###